Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 07039-409US1	Application No. 10/561,014	
by A	closure Statement pplicant	Applicant Shuchong Pan et al.		
(Use several sheets if necessary) (37 CFR §1.98(b))		Filing Date December 16, 2005	Group Art Unit 1649	

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	1	4,034,074	07/05/77	Miles			
	2	4,098,876	07/04/78	Piasio et al.			
	3	4,233,402	11/11/80	Maggio et al.			
	4	4,996,143	02/26/91	Heller et al.			
	5	5,114,923	05/19/92	Seilhamer et al.		-,	
	6	5,296,347	03/22/94	LaMotte, III			
	7	5,565,322	10/15/96	Heller			
	8	5,580,859	12/03/96	Felgner et al.			
	9	5,583,108	12/10/96	Wei et al.			
	10	5,589,466	12/31/96	Felgner et al.			
	11	5,849,489	12/15/98	Heller			
	12	6,124,430	09/26/00	Mischak et al.			
	13	6,162,603	12/19/00	Heller			
	14	6,376,207	04/23/02	Mischak et al.			

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner	0	Document	Publication	Country or			Translation	
Initial	ID	Number	Date	Patent Office	Class	Subclass	Yes	No
	15	WO 84/03825	10/11/84	WIPO				
	16	WO 00/71576	11/30/00	WIPO				
	17	WO 01/44284	06/21/01	WIPO				

Other Documents (include Author, Title, Date, and Place of Publication)					
Examiner	Desig.				
Initial	ID	Document			
	18	Abdelhafiz, "Heart failure in older people: causes, diagnosis and treatment," Age Ageing, 2002, 31(1):29-36			
	19	Best et al., "Dendroaspis natriuretic peptide relaxes isolated human arteries and veins," <u>Cardiovas.</u> Res., 2002, 55:375-384			
	20	Burger and Burger, "BNP in decompensated heart failure: Diagnostic, prognostic and therapeutic potential," Curr. Opin. Investig. Drugs, 2001, 2(7):929-35			

Examiner Signature	Date Considered				
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

	Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 07039-409US1	Application No. 10/561,014	
Information Disclosure Statement by Applicant			Applicant Shuchong Pan et al.		
(Use several sheets if necessary) (37 CFR §1.98(b))		Filing Date December 16, 2005	Group Art Unit 1649		

Other Documents (include Author, Title, Date, and Place of Publication)				
Examiner	Desig.			
Initial	ID_	Document		
	21	Chaurand et al., "Peptide and Protein Identification by Matrix-Assisted Laser Desorption Ionization		
	21	(MALDI) and MALDI-Post-Source Decay Time-of-Flight Mass Spectrometry," J. Am. Soc. Mass Spectrom., 1999, 10(2):91-103		
		Cole et al., "The EBV-Hybridoma Technique and Its Application to Human Lung Cancer,"		
	22	Monoclonal Antibodies and Cancer Therapy, 1985, Alan R. Liss, Inc., pp. 77-96		
		Cote et al., "Generation of human monoclonal antibodies reactive with cellular antigens," Proc. Natl.		
	23	Acad. Sci. USA, 1983, 80:2026-2030		
	24	Cowie and Mendez, "BNP and Congestive Heart Failure," <u>Prog. Cardiovasc. Dis.</u> , 2002, 44(4):293-321		
	25	Gevaert et al., "Protein identification based on matrix assisted laser desorption/ionization-post		
	23	source decay-mass spectrometry," Electrophoresis, 2001, 22(9):1645-51		
	26	Guatelli et al., "Isothermal, in vitro amplification of nucleic acids by a multienzyme reaction		
	20	modeled after retroviral replication," Proc. Natl. Acad. Sci. USA, 1990, 87:1874-1878		
	27	Huse et al., "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda," <u>Science</u> , 1989, 246:1275-1281		
	28	Hyrup and Nielsen, "Peptide Nucleic Acids (PNA): Synthesis, Properties and Potential		
20		Applications," Bioorgan. Med. Chem., 1996, 4:5-23		
	29	Köhler and Milstein, "Continuous cultures of fused cells secreting antibody of predefined		
		specificity," Nature, 1975, 256:495-497		
	30	Kozbor and Roder, "The production of monoclonal antibodies from human lymphocytes,"  Immunology Today, 1983, 4:72-79		
		Lewis, "PCR's Competitors Are Alive and Well and Moving Rapidly Towards Commercialization,"		
	31	Genetic Engineering News, 1992, 12(9):1-3		
	32	Peacock, "The B-type natriuretic peptide assay: a rapid test for heart failure," <u>Cleve. Clin. J. Med.</u> , 2002, 69(3):243-251		
	33	Richards et al., "BNP in hormone-guided treatment of heart failure," <u>Trends Endocrinol. Metab.</u> , 2002, (5):151-155		
	34	Sagnella, "Practical implications of current natriuretic peptide research," J. Renin. Angiotensin Aldosterone Syst., 2000, 1(4):304-315		
	2.5	Ausubel et al. (eds.), Short Protocols in Molecular Biology, 1992, Chapters 8 and 11, Green		
	35	Publishing Associates and John Wiley & Sons		
	36	Summerton and Weller, "Morpholino Antisense Oligomers: Design, Preparation, and Properties,"		
		Antisense Nucleic Acid Drug Dev., 1997, 7:187-195		
	37	Tremblay et al., "Biochemistry and physiology of the natruiretic peptide receiptor guanylyl		
		cyclases," Mol. Cell. Biochem., 2002, 230(1-2):31-47		
	38	Walther et al., "Natriuretic peptide system in fetal heart and circulation," J. Hypertens., 2002, 20(5):786-791		
	39	Weiss, "Hot Prospect for New Gene Amplifier," Science, 1991, 254:1292-1293		

Examiner Signature	Date Considered			
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				